Methods and compositions for inhibiting cd32b expressing cells

Abstract

The present invention relates to immunoglobulins that bind FcγRIIb+ cells and coengage the antigen on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.

We claim: 
     
         1 . An antibody having affinity for CD40 comprising:
 a means for binding CD40; and   an IgG1 Fc domain comprising an Fc modification comprising the amino acid substitution S267E in an Fc region, wherein the numbering is according to the EU index, as in Kabat.   
     
     
         2 . The antibody of  claim 1 , wherein the Fc modification consists of the amino acid substitution S267E in the Fc. 
     
     
         3 . A pharmaceutical composition comprising the antibody of  claim 1  and a pharmaceutically acceptable carrier. 
     
     
         4 . The pharmaceutical composition of  claim 3 , wherein the antibody is in a water soluble-form. 
     
     
         5 . The pharmaceutical composition of  claim 3 , wherein the composition is formulated for injection. 
     
     
         6 . The pharmaceutical composition of  claim 3 , wherein the composition is a sustained release formulation. 
     
     
         7 . The pharmaceutical composition of  claim 3 , wherein the composition further comprises a chemotherapeutic agent. 
     
     
         8 . The pharmaceutical composition of  claim 7 , wherein the chemotherapeutic agent is a taxane. 
     
     
         9 . A kit comprising the pharmaceutical composition of  claim 3  and a chemotherapeutic agent. 
     
     
         10 . The kit of  claim 9  wherein the chemotherapeutic agent is a taxane. 
     
     
         11 . A method of activating a B cell or a dendritic cell comprising contacting a B cell or a dendritic cell with the antibody of  claim 1 . 
     
     
         12 . A method of activating a B cell or a dendritic cell comprising contacting a B cell or a dendritic cell with the antibody of  claim 2 .